Journal of palliative medicine
August 1, 2022
William E Rosa, Zachary Sager, Megan Miller et al.
49 citations
Psychedelic-assisted therapy (PAT) is a promising treatment for conditions like treatment-resistant depression, substance use disorder, and PTSD. In palliative care, a single PAT session can produce lasting reductions in anxiety, depression, and demoralization—symptoms that harm quality of life for seriously ill and end-of-life patients. Although interest in psychedelics has revived, few resources exist for applying PAT in hospice and palliative care. This article provides 10 evidence-informed tips for palliative care clinicians, developed with international experts, to help familiarize teams with PAT, address legal and logistical barriers, discuss therapeutic competencies, and highlight approaches to maximize safety and benefits for patients and caregivers.
Journal of Psychedelic Studies
January 1, 2025
Beatriz Caiuby Labate, Henrique Fernandes Antunes, Jamie Beachy et al.
6 citations
Mainstreaming psychedelics carries tensions, controversies, and risks that require careful assessment. Overemphasis on biomedicalization sidelines social sciences, humanities, and traditional knowledge. Policy challenges, commodification dangers, and ecological burdens from expanded use are examined. The psychotherapeutic approach to care has been neglected. Inclusion, ethics, and reciprocity are needed to avoid recreating the psychedelic movement as another expression of mainstream capitalism. With the FDA's delay in approving MDMA for PTSD and regulatory hurdles in places like Colorado and Oregon, an informed conversation about the future is urgent, avoiding romanticization and addressing contemporary challenges and ethical risks.
Am J Bioeth
January 13, 2025
Jamie Beachy, Willa Hall, Chantelle Thomas et al.
2 citations
Therapists with extensive clinical experience in MDMA-assisted therapy (MAT) for adults with PTSD in Phase 3 trials offer their perspective in response to a prior article. They draw on their direct work to address points raised, likely clarifying or correcting aspects of MAT's implementation or outcomes. The text indicates their hands-on role in these trials but does not present new findings, data, or a specific argument beyond offering a response based on their experience.